Trial Profile
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-242
- 06 Oct 2022 According to an OncoCyte Corporation media release, DetermaIO will become a defined secondary endpoint for the ongoing clinical trial. If successful, the study will support the use of DetermaIO to identify patients who received standard pre-operative chemotherapy, that would likely benefit from a year of Keytruda treatment after surgery.
- 06 Oct 2022 According to an OncoCyte Corporation media release, DetermaIO has been selected by the SWOG Cancer Research Network to be used in a prospectively designed biomarker study of breast cancer tissues. These tissues were collected during this study.
- 01 Jul 2021 Status changed from recruiting to active, no longer recruiting.